ArticleBreast cancer research : BCR2014
Outcomes of children exposed in utero to chemotherapy for breast cancer.
Article in Breast cancer research : BCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00510367 (Multimodality Treatment of Primary Breast Cancer Occurring Concomitant With Pregnancy), which is not on this map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multimodality Treatment of Primary Breast Cancer Occurring Concomitant With Pregnancy
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- The Asia Pacific League of Associations for Rheumatology (APLAR) Consensus Statements for the Management of Reproductive Issues in Autoimmune Rheumatic Diseases.International journal of rheumatic diseases · 2026Pooled it
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- Perinatal outcomes for infants exposed to systemic cancer treatment during gestation: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Plasma concentrations of doxorubicin and cyclophosphamide during anthracycline-based chemotherapy in a pregnant breast cancer patient: evaluation of gestational changes.Cancer chemotherapy and pharmacology · 2026Article
- Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant inFrontiers in oncology · 2026Article
- Cancer chemotherapy in pregnancy and adverse pediatric outcomes: a population-based cohort study.Journal of the National Cancer Institute · 2025Article
- The impact ofHuman reproduction open · 2025Review
- Breast cancer during pregnancy-The oncologist's point of view.Acta obstetricia et gynecologica Scandinavica · 2024Article
- Treatment of metastatic rectal squamous cell carcinoma in a pregnant patient.BMJ case reports · 2024Article
- Neonatal outcomes and follow-up of children born to women with pregnancy-associated cancer: a prospective observational study.BMC pregnancy and childbirth · 2024Observational
- Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories.Frontiers in pharmacology · 2024Review
- Pregnancy and Breast Cancer: A Challenge for the Multidisciplinary Team. A Single Center Experience and Narrative Review.OncoTargets and therapy · 2024Article
- Cancer and Pregnancy in the Post-Roe v. Wade Era: A Comprehensive Review.Current oncology (Toronto, Ont.) · 2023Review
- 2022 Chinese guideline for the management of pregnancy and reproduction in systemic lupus erythematosus.Rheumatology and immunology research · 2023Review
- Adverse birth outcomes of adolescent and young adult women diagnosed with cancer during pregnancy.Journal of the National Cancer Institute · 2023Article
- Cancer in pregnancy: breast cancer.Abdominal radiology (New York) · 2023Review
- What Is Known about Breast Cancer in Young Women?Cancers · 2023Review
- Management of urachal cancer in pregnancy: A systematic review.BJUI compass · 2022Review
- Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy.Cancer medicine · 2022Article
- Gestational breast cancer in a patient with Crohn's disease: two case reports.Journal of medical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe incidence of breast cancer diagnosed during pregnancy is expected to increase as more women delay childbearing in the United States. Treatment of cancer in pregnant women requires prudent judgment to balance the benefit to the cancer patient and the risks to the fetus. Prospective data on the outcomes of children exposed to chemotherapy in utero are limited for the breast cancer population.
methodsBetween 1992 and 2010, 81 pregnant patients with breast cancer were treated in a single-arm, institutional review board-approved study with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) in the adjuvant or neoadjuvant setting. Labor and delivery records were reviewed for each patient and neonate. In addition, the parents or guardians were surveyed regarding the health outcomes of the children exposed to chemotherapy in utero.
resultsIn total, 78% of the women (or next of kin) answered a follow-up survey. At a median age of 7 years, most of the children exposed to chemotherapy in utero were growing normally without any significant exposure-related toxicity or health problems. Three children were born with congenital abnormalities: one each with Down syndrome, ureteral reflux or clubfoot. The rate of congenital abnormalities in the cohort was similar to the national average of 3%.
conclusionsDuring the second and third trimesters, pregnant women with breast cancer can be treated with FAC safely without concerns for serious complications or short-term health concerns for their offspring who are exposed to chemotherapy in utero. Continued long-term follow-up of the children in this cohort is required.
trial registrationClinicalTrials.gov Identifier: NCT00510367. Other Study ID numbers: ID01-193, NCI-2012-01578. Registration date: 31 July 2007.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.